The Use of 5-Alpha Reductase Inhibitors and Alpha-1 Blockers Does Not Improve Clinical Outcome in Male Patients Undergoing Radical Cystectomy for Bladder Cancer in Quebec, Canada.
Adrenergic alpha-1 antagonists
Survival
Urinary bladder neoplasms
Journal
Clinical genitourinary cancer
ISSN: 1938-0682
Titre abrégé: Clin Genitourin Cancer
Pays: United States
ID NLM: 101260955
Informations de publication
Date de publication:
08 2021
08 2021
Historique:
received:
02
12
2020
revised:
30
01
2021
accepted:
31
01
2021
pubmed:
8
3
2021
medline:
11
9
2021
entrez:
7
3
2021
Statut:
ppublish
Résumé
Existing literature suggests that bladder cancer (BC) outcome may be improved when patients use 5α-reductase inhibitors and/or α Using provincial health administrative databases, we retrospectively identified male BC patients undergoing RC in Quebec province between 2000 and 2015, and we collected data from 2 years before RC until December 2016 or death. Survival analyses were conducted using Kaplan-Meier curves, log-rank tests, propensity score matching, and uni- and multivariable Cox proportional hazards models. Covariates included age, Charlson's comorbidity index, region of residence, year of RC, distance to hospital, hospital type, annual RC volume of each hospital and surgeon, neoadjuvant chemotherapy use, and type of bladder diversion. Of the 2822 patients included, 284 patients used 5α-reductase inhibitors and 1001 patients used α Preoperative use of 5α-reductase inhibitors and α
Sections du résumé
BACKGROUND
Existing literature suggests that bladder cancer (BC) outcome may be improved when patients use 5α-reductase inhibitors and/or α
PATIENTS AND METHODS
Using provincial health administrative databases, we retrospectively identified male BC patients undergoing RC in Quebec province between 2000 and 2015, and we collected data from 2 years before RC until December 2016 or death. Survival analyses were conducted using Kaplan-Meier curves, log-rank tests, propensity score matching, and uni- and multivariable Cox proportional hazards models. Covariates included age, Charlson's comorbidity index, region of residence, year of RC, distance to hospital, hospital type, annual RC volume of each hospital and surgeon, neoadjuvant chemotherapy use, and type of bladder diversion.
RESULTS
Of the 2822 patients included, 284 patients used 5α-reductase inhibitors and 1001 patients used α
CONCLUSION
Preoperative use of 5α-reductase inhibitors and α
Identifiants
pubmed: 33676834
pii: S1558-7673(21)00030-6
doi: 10.1016/j.clgc.2021.01.007
pii:
doi:
Substances chimiques
5-alpha Reductase Inhibitors
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
371-371.e9Subventions
Organisme : CIHR
Pays : Canada
Informations de copyright
Copyright © 2021 Elsevier Inc. All rights reserved.